Search research articles
Contact Us
Filters
Showing results (41-50 of 53) with videos related to
Page
of 6
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
June 8, 2022
Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS
Douglas L Arnold, Till Sprenger, Amit Bar-Or, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology
|
March 10, 2024
Visual evoked potentials in multiple sclerosis: P100 latency and visual pathway damage including the lateral geniculate nucleus
Athina Papadopoulou, Armanda Pfister, Charidimos Tsagkas, et al.
Journal of Neurology
|
March 4, 2020
Efficacy of inpatient personalized multidisciplinary rehabilitation in multiple sclerosis: behavioural and functional imaging results
Priska Zuber, Charidimos Tsagkas, Athina Papadopoulou, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
May 26, 2019
Attack-related damage of thalamic nuclei in neuromyelitis optica spectrum disorders
Athina Papadopoulou, Frederike Cosima Oertel, Laura Gaetano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
April 16, 2025
Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS
Douglas L Arnold, Shannon Kolind, Haz-Edine Assemlal, et al.
Multiple Sclerosis and Related Disorders
|
December 10, 2020
Ventral posterior nucleus volume is associated with neuropathic pain intensity in neuromyelitis optica spectrum disorders
Susanna Asseyer, Joseph Kuchling, Laura Gaetano, et al.
Neuroimage. Clinical
|
September 6, 2022
A comparative assessment of myelin-sensitive measures in multiple sclerosis patients and healthy subjects
Reza Rahmanzadeh, Matthias Weigel, Po-Jui Lu, et al.
Ebiomedicine
|
June 24, 2023
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
Amit Bar-Or, Gian-Andrea Thanei, Christopher Harp, et al.
Science Translational Medicine
|
October 12, 2012
Neural stem cell engraftment and myelination in the human brain
Nalin Gupta, Roland G Henry, Jonathan Strober, et al.
Nature Medicine
|
August 20, 2025
AI-driven reclassification of multiple sclerosis progression
Habib Ganjgahi, Dieter A Häring, Piet Aarden, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 53) with videos related to
Sort By:
Page
of 6
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
June 8, 2022
Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS
Douglas L Arnold, Till Sprenger, Amit Bar-Or, et al.
Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology
|
March 10, 2024
Visual evoked potentials in multiple sclerosis: P100 latency and visual pathway damage including the lateral geniculate nucleus
Athina Papadopoulou, Armanda Pfister, Charidimos Tsagkas, et al.
Journal of Neurology
|
March 4, 2020
Efficacy of inpatient personalized multidisciplinary rehabilitation in multiple sclerosis: behavioural and functional imaging results
Priska Zuber, Charidimos Tsagkas, Athina Papadopoulou, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
May 26, 2019
Attack-related damage of thalamic nuclei in neuromyelitis optica spectrum disorders
Athina Papadopoulou, Frederike Cosima Oertel, Laura Gaetano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
April 16, 2025
Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS
Douglas L Arnold, Shannon Kolind, Haz-Edine Assemlal, et al.
Multiple Sclerosis and Related Disorders
|
December 10, 2020
Ventral posterior nucleus volume is associated with neuropathic pain intensity in neuromyelitis optica spectrum disorders
Susanna Asseyer, Joseph Kuchling, Laura Gaetano, et al.
Neuroimage. Clinical
|
September 6, 2022
A comparative assessment of myelin-sensitive measures in multiple sclerosis patients and healthy subjects
Reza Rahmanzadeh, Matthias Weigel, Po-Jui Lu, et al.
Ebiomedicine
|
June 24, 2023
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
Amit Bar-Or, Gian-Andrea Thanei, Christopher Harp, et al.
Science Translational Medicine
|
October 12, 2012
Neural stem cell engraftment and myelination in the human brain
Nalin Gupta, Roland G Henry, Jonathan Strober, et al.
Nature Medicine
|
August 20, 2025
AI-driven reclassification of multiple sclerosis progression
Habib Ganjgahi, Dieter A Häring, Piet Aarden, et al.
Page
of 6